98 related articles for article (PubMed ID: 19783961)
1. Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue.
Bazas VM; Lukyanova NY; Lisovenko GS; Rozumiy DO; Potebnya GP
Exp Oncol; 2009 Sep; 31(3):182-4. PubMed ID: 19783961
[TBL] [Abstract][Full Text] [Related]
2. Relation between cell-to-cell adhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer.
Bazas VM; Lukyanova NY; Demash DV; Galakhin KO; Myasoedov DV
Exp Oncol; 2008 Sep; 30(3):235-9. PubMed ID: 18806748
[TBL] [Abstract][Full Text] [Related]
3. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.
Lieto E; Ferraraccio F; Orditura M; Castellano P; Mura AL; Pinto M; Zamboli A; De Vita F; Galizia G
Ann Surg Oncol; 2008 Jan; 15(1):69-79. PubMed ID: 17896140
[TBL] [Abstract][Full Text] [Related]
4. Re-expression of the cadherin-catenin complex in lymph nodes with metastasis in advanced gastric cancer: the relationship with patient survival.
Liu J; Ikeguchi M; Nakamura S; Kaibara N
J Exp Clin Cancer Res; 2002 Mar; 21(1):65-71. PubMed ID: 12071532
[TBL] [Abstract][Full Text] [Related]
5. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.
Chung GG; Zerkowski MP; Ocal IT; Dolled-Filhart M; Kang JY; Psyrri A; Camp RL; Rimm DL
Cancer; 2004 May; 100(10):2084-92. PubMed ID: 15139049
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
7. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.
Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR
J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858
[TBL] [Abstract][Full Text] [Related]
9. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
12. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
15. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
[TBL] [Abstract][Full Text] [Related]
16. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer.
Tanaka M; Kitajima Y; Edakuni G; Sato S; Miyazaki K
Br J Surg; 2002 Feb; 89(2):236-44. PubMed ID: 11856141
[TBL] [Abstract][Full Text] [Related]
18. Expression of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex correlates with the macroscopic appearance of early gastric cancer.
Ohene-Abuakwa Y; Noda M; Perenyi M; Kobayashi N; Kashima K; Hattori T; Pignatelli M
J Pathol; 2000 Dec; 192(4):433-9. PubMed ID: 11113859
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma.
Inada T; Kikuyama S; Ichikawa A; Igarashi S; Ogata Y
Anticancer Res; 1998; 18(3B):2003-10. PubMed ID: 9677457
[TBL] [Abstract][Full Text] [Related]
20. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
